Phase 3 trial of Biogen and UCB's dapirolizumab pegol shows significant improvement in lupus disease activity. Read more here ...

01 优时比和渤健公布了3期PHOENYCS GO研究的详细结果，显示dapirolizumab pegol与标准治疗联用显著改善中度至重度系统性红斑狼疮患者的疾病活动程度。 今日，优时比（UCB）和渤健（Biogen）公布了3期PHOENYCS ...

Biogen Idec Inc的股价已触及52周低点，交易价格为156.9美元，反映出这家生物技术公司正经历一段充满挑战的时期。过去一年，该公司股价下跌了31.68%，表明投资者存在重大担忧，市场压力较大。这一下滑发生在整个行业波动性较大的背景下，同时公司还面临着特定的障碍，包括竞争激烈的市场动态和产品管线的挫折。投资者正密切关注Biogen的战略举措，以重振增长并重获市场信心。 在其他近期新闻中 ...

We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at ...

After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...

Trump fingers Robert F. Kennedy Jr. to lead the HHS, lupus and ATTR-CM dominate headlines this week, bluebird bio has a cash gap to leap and RegenxBio eyes Sarepta in Duchenne muscular dystrophy.

Needham has downgraded Biogen (BIIB) to hold from buy, citing a lack of near-term catalysts and slow uptake for the company’s ...

Needham downgraded Biogen Inc (NASDAQ:BIIB), citing limited catalysts for the company over the next year. Alzheimer’s drug ...

Biogen (NASDAQ:BIIB – Get Free Report) was downgraded by equities research analysts at Needham & Company LLC from a “buy” ...

Needham downgraded Biogen (BIIB) to Hold from Buy without a price target The firm does not see a meaningful source of upside for the shares ...

周三，花旗开始对Biogen (NASDAQ:BIIB)股票进行覆盖，给予中性评级，并设定190美元的目标价。这一新的覆盖反映了对这家生物技术公司财务前景的谨慎态度，主要是由于其传统业务面临压力。 Biogen的核心产品，包括用于多发性硬化症(MS)、脊髓性肌萎缩症(SMA)的治疗以及来自抗CD20疗法的特许权使用费，年复合增长率(CAGR)分别下降了12%、3%和2%。为了应对这些下降，公司致力 ...

(RTTNews) - UCB and Biogen Inc. (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, a Fc-free anti-CD40L drug candidate, showing significant clinical ...